| 0.6361 0.077 (13.71%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.8 |
1-year : | 0.94 |
| Resists | First : | 0.68 |
Second : | 0.8 |
| Pivot price | 0.58 |
|||
| Supports | First : | 0.58 |
Second : | 0.52 |
| MAs | MA(5) : | 0.59  |
MA(20) : | 0.57 |
| MA(100) : | 0.7 |
MA(250) : | 0.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 41.5 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 1.54 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LEXX ] has closed below upper band by 8.5%. Bollinger Bands are 40.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.65 | 0.65 - 0.65 |
| Low: | 0.54 - 0.55 | 0.55 - 0.55 |
| Close: | 0.63 - 0.64 | 0.64 - 0.64 |
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Mon, 13 Jul 2026
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Mon, 13 Jul 2026
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Fri, 10 Jul 2026
LEXX Q3'26 Earnings: revenue estimate is 0 USD - TradingView
Mon, 06 Jul 2026
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
Thu, 25 Jun 2026
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Wed, 17 Jun 2026
Lexaria Bioscience (LEXX) Advances Drug Delivery Technology - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.404e+007 (%) |
| Held by Institutions | 3.3 (%) |
| Shares Short | 350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.13e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 259.5 % |
| Return on Equity (ttm) | -76 % |
| Qtrly Rev. Growth | 368000 % |
| Gross Profit (p.s.) | -260.3 |
| Sales Per Share | -432.56 |
| EBITDA (p.s.) | 1.08235e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.83 |
| Dividend | 0 |
| Forward Dividend | 343120 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|